India's largest vial maker expects sales to triple on COVID-19 vaccine ramp up

Bengaluru: Indian drug vial maker Schott Kaisha is expecting annual vial sales for COVID-19 shots to more than triple as vaccine production, including by one of its top customers Serum Institute, increases in response to a monster second wave of infections.

An Indo-German joint venture between specialty glass makers Schott AG and Kaisha, the company expects to sell 380 million vials for COVID-19 vaccines in 2021-22, up from 113 million a year earlier, Director Rishad Dadachanji said in an interview. "The demand from our major customers has gone up two-fold, and is indicated to go up three-fold in the near future," Dadachanji said.